8-K: Aethlon Medical Cuts Costs, Advances Cancer & Long COVID Trials

Aethlon Medical reported a 48% reduction in operating expenses for fiscal Q2 2025 while progressing its Australian oncology trial and Long COVID research.

Summary

• Fiscal Q2 2025 operating expenses decreased by 48% to approximately $1.5 million from $2.9 million in Q2 2024.
• Net loss for Q2 2025 was approximately $1.49 million, an improvement from $2.81 million in Q2 2024.
• Cash balance as of September 30, 2025, was approximately $5.8 million.
• Recruitment is underway for Cohort 2 of the Australian oncology trial for the Hemopurifier under an amended protocol.
• Ongoing collaboration with UCSF on Long COVID research, with a manuscript in preparation for peer-reviewed journal submission.
• Initiated evaluation of Hemopurifier compatibility with a simplified blood treatment system.
• Maintained Nasdaq listing by resolving compliance matters.

Sentiment

Score: 7

Explanation: The company demonstrated strong financial discipline with a significant reduction in operating expenses and an improved net loss. Clinical and research programs are advancing, including progress in the Australian oncology trial and Long COVID research. However, the company still operates at a loss and explicitly states a potential need for additional financing within 12 months, which tempers the overall positive sentiment.

Positives

• Operating expenses decreased significantly by 48% (approximately $1.4 million) in Q2 2025, reflecting disciplined cost management.
• Net loss improved to approximately $1.49 million in Q2 2025 from $2.81 million in Q2 2024.
• Successfully resolved Nasdaq compliance matters, maintaining listing on the Capital Market.
• Advanced the Australian oncology trial with recruitment for Cohort 2 underway under an amended protocol allowing combination therapies with Pembrolizumab or Nivolumab.
• Observed positive exploratory findings from Cohort 1 of the oncology trial, including decreases in large EVs (microvesicles) and PD-L1 carrying EVs, and improvements in immunotherapy-associated laboratory ratios in some participants.
• Continued scientific collaboration with UCSF on Long COVID research, with a manuscript being prepared for peer-reviewed publication.
• Initiated evaluation of Hemopurifier compatibility with a simplified blood treatment system, potentially streamlining future treatments in oncology units.
• Maintained a cash balance of approximately $5.8 million as of September 30, 2025.

Negatives

• The company reported a continued net loss of approximately $1.49 million for the quarter ended September 30, 2025.
• Cash on hand may not be sufficient to support operations for the next 12 months without additional financing, as stated in forward-looking statements.
• Exploratory findings from Cohort 1 of the oncology trial are from an early feasibility study and should not be interpreted as evidence of clinical benefit or safety beyond study parameters; observations regarding T cell numbers did not show a consistent pattern in terms of timing of improvement.
• The unmet need for cancer patients receiving pembrolizumab or nivolumab remains significant, with only approximately 30-40% having lasting clinical responses.

Risks

• Cash on hand may not be sufficient to support operations for the next 12 months without additional financing.
• Ability to raise additional capital on terms favorable to the company, or at all.
• Ability to successfully complete development of the Hemopurifier.
• Ability to successfully demonstrate the utility and safety of the Hemopurifier in cancer and infectious diseases and in the transplant setting.
• Ability to achieve and realize anticipated benefits from operational and financial milestones.
• Ability to maintain Nasdaq listing.
• Ability to obtain approval from the Ethics Committee of its third location in Australia, including on the timeline expected.
• Ability to enroll additional patients in its oncology clinical trial in Australia, including on the timeline expected.
• Ability to manage and successfully complete its clinical trials.
• Ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials.
• Unforeseen changes in regulatory requirements.
• Ability to further research potential applications of the Hemopurifier in other EV-associated diseases and other potential risks.

Future Outlook

The company aims to continue advancing its clinical and research strategy while maintaining operational discipline, with the long-term goal of developing therapeutic solutions for cancer and life-threatening infectious diseases. Exploratory findings from current trials are expected to inform the design of future efficacy and safety trials, including a Premarket Approval (PMA) study. Research into Hemopurifier compatibility with simplified blood treatment systems could lead to easier deployment in oncology units.

Management Comments

• "Our ongoing trial progress, research collaborations, and technology initiatives continue to support our long-term goal of developing therapeutic solutions for cancer and life-threatening infectious diseases." James Frakes, CEO and CFO.
• "We remain focused on executing our clinical and research strategy while maintaining operational discipline." James Frakes, CEO and CFO.
• "We believe the unmet need remains significant: currently, only approximately 30-40% of patients who receive pembrolizumab or nivolumab will have lasting clinical responses to these agents."

Industry Context

Aethlon Medical operates in the highly competitive and regulated medical therapeutic device industry, focusing on oncology and infectious diseases. The company's Hemopurifier targets extracellular vesicles (EVs), which are increasingly recognized for their role in cancer progression and resistance to immunotherapies like PD-1 agents (e.g., Pembrolizumab, Nivolumab). Addressing the low response rates (30-40%) to current PD-1 therapies represents a significant unmet medical need. The research into Long COVID also places Aethlon within the growing field of post-viral syndrome treatments. The focus on operational efficiency and cost reduction is a common trend for clinical-stage biotech companies managing burn rates while advancing R&D.

Related Party Transactions

• Due to related parties decreased from $579,565 as of March 31, 2025, to $248,454 as of September 30, 2025.

Stakeholder Impact

• Shareholders: Potential positive impact from reduced operating expenses and clinical progress, but dilution risk from potential future capital raise.
• Patients (Cancer/Long COVID): Potential future therapeutic benefits from the Hemopurifier if trials are successful.
• Employees: Lower headcount mentioned as a reason for reduced payroll expenses, indicating past or ongoing workforce adjustments.
• Creditors: Reduced "Due to related parties" could indicate improved short-term liquidity management.

Next Steps

• Continue recruitment for Cohort 2 of the Australian oncology trial.
• Analyze additional data from subsequent cohorts of the oncology trial to determine reproducibility and dose response.
• Prepare and submit the Long COVID research manuscript for peer-reviewed publication.
• Continue evaluation of Hemopurifier compatibility with an alternative, simplified blood treatment system.
• Design future efficacy and safety trials, including a Premarket Approval (PMA) study, based on exploratory findings.

Key Dates

Recommendation

While Aethlon Medical has shown commendable progress in cost reduction and clinical trial advancement, the company remains in a clinical-stage with no revenue-generating products. The explicit disclosure of potential need for additional financing within 12 months introduces significant dilution risk. The positive clinical data is still exploratory and requires further validation. Investors should hold to monitor the progress of clinical trials and the company's ability to secure future funding without excessive dilution, as well as the transition from exploratory findings to definitive efficacy and safety trials.

Keywords

Aethlon Medical, AEMD, Hemopurifier, Oncology, Cancer Treatment, Long COVID, Extracellular Vesicles, Clinical Trials, Medical Device, Biotechnology, Financial Results, Cost Reduction, Nasdaq Listing